IP Library Granted Patent US 9,464,272
Granted Patent B2
US 9,464,272 · App. 14/567,457 · Granted Oct 11, 2016

Cell-derived composition

Inventors: Malcolm A Meyn, III (Pittsburgh, PA); Christopher A Fried (Pittsburgh, PA); Donna M Olejniczak (Pittsburgh, PA); Randall G Rupp (Swanton, VT)
Assignee: STEMNION, INC.
C12N5/0605A61K35/50A61K38/19C12N2501/11C12N2501/998C12N2502/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,272
App. No.
14/567,457
Granted
Oct 11, 2016
Kind
B2
Abstract

The invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this composition to promote bone growth and/or regeneration and/or repair.

Claims (5)

1. A composition comprising Amnion-derived Cellular Cytokine Solution-B (ACCS-B), wherein the composition is made by a method comprising the step of culturing Amnion-derived Multipotent Progenitor (AMP) cells in Basal Medium Eagle (BME) culture medium supplemented with human serum albumin and recombinant human EGF.

2. The composition of claim 1 which is a pharmaceutical composition.

3. The composition of claim 1 which is formulated for sustained-release (SR).

4. A method for promoting bone growth comprising administering to a subject in need thereof a therapeutically effective dose of a composition selected from the group consisting of ACCS-B and SR-ACCS-B.

5. A method for making ACCS-B comprising the step of culturing Amnion-derived Multipotent Progenitor (AMP) cells in Basal Medium Eagle (BME) culture medium supplemented with human serum albumin and recombinant human EGF.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 29, 2022
From: NOVEOME BIOTHERAPEUTICS, INC.
To: UNITED STATES GOVERNMENT
Reel/Frame 059527/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2015
From: MEYN, MALCOLM A, 111; FRIED, CHRISTOPHER A; OLEJNICZAK, DONNA M; RUPP, RANDALL G
To: STEMNION, INC.
Reel/Frame 035093/0007 →
Continuity (2)
Provisional Application 61915054 · Dec 12, 2013
Related Publication 20150166951A1 · Jun 18, 2015